No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ESNT Essent
- 53.730
- -0.440-0.81%
Trading Apr 25 09:30 ET
5.74BMarket Cap8.27P/E (TTM)
53.730High53.730Low1.73KVolume53.740Open54.170Pre Close92.68KTurnover0.00%Turnover Ratio8.27P/E (Static)106.75MShares59.90052wk High1.12P/B5.55BFloat Cap39.50052wk Low1.00Dividend TTM103.28MShs Float59.900Historical High1.86%Div YieldTTM0.00%Amplitude15.033Historical Low53.730Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NYSE Order Imbalance 82219.0 Shares on Buy Side 82219.0 Shares on Buy Side
Press Release: Essent Group Ltd. Schedules First Quarter Earnings Conference Call for May 3, 2024
Essent Group Ltd. Schedules First Quarter Earnings Conference Call for May 3, 2024 HAMILTON, Bermuda--(BUSINESS WIRE)--April 12, 2024-- Essent Group Ltd. (NYSE: ESNT) today announced that it will ho
Essent Group Insiders Sold US$3.1m Of Shares Suggesting Hesitancy
Over the past year, many Essent Group Ltd. (NYSE:ESNT) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more
Essent Group Is Maintained at Market Perform by Keefe, Bruyette & Woods
Essent Group Is Maintained at Market Perform by Keefe, Bruyette & Woods
Express News | Keefe, Bruyette & Woods Maintains Market Perform on Essent Group, Raises Price Target to $64
Ally, Guild, Essent Downgraded, Navient Upgraded at J.P. Morgan in Q1 Preview
Comments
Essent Group's low P/E ratio is attributed to its underwhelming earnings and the forecast of this trend persisting. Investors are hesitant to pay more for the stock due to limited growth prospects, keeping the share price from a significant rise.
Essent Group Ltd.'s (NYSE:ESNT) Price Is Right But Growth Is Lacking 1
Gibbons' insiders selling shares below market price hints at contentment with lower valuation, possibly suggesting shares are fully valued. The high inside ownership shows management's interests might align with shareholders', but recent sales can cause concern.
Insider sell-off at current prices hints at doubt in the company's future. Coupled with a lack of purchases recently, this signals caution towards the stock. High insider ownership, however, suggests a vested interest in long-term success.
ColumnsBofA: 14 stocks likely to beat earnings estimates
$Interactive Brokers(IBKR.US$$Alcoa(AA.US$$Knight-Swift Transportation(KNX.US$$Crane(CR.US$$AutoNation(AN.US$$Boyd Gaming(BYD.US$$Harley-Davidson(HOG.US$$ASGN Inc(ASGN.US$$Community Health Systems(CYH.US$$Option Care Health(OPCH.US$$WEX Inc(WEX.US$$TTEC Holdings(TTEC.US$$Louisiana-Pacific(LPX.US$$Essent(ESNT.US$
Expand 19
2
ColumnsToday's pre-market stock movers: NIO, XPEV, AAPL, NVDA and more
Gainers:
• $SailPoint Technologies(SAIL.US$ +30% (confirms agreement to be acquired by Thoma Bravo for $6.9 bln; stockholders to receive $65.25 per share in cash)
• $Veru Inc(VERU.US$ +28.9% (Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy)
• $Affimed NV(AFMD.US$ +12.9% (Presents Upda...
• $SailPoint Technologies(SAIL.US$ +30% (confirms agreement to be acquired by Thoma Bravo for $6.9 bln; stockholders to receive $65.25 per share in cash)
• $Veru Inc(VERU.US$ +28.9% (Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy)
• $Affimed NV(AFMD.US$ +12.9% (Presents Upda...
21
4
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg